Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06160128 · ClinicalTrials.gov registry record

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

A clinical trial of Influenza and RSV, sponsored by VA Office of Research and Development.

Recruiting
Registry status
400,000
Enrollment target
1
Study location

NCT06160128: Recruiting study of Influenza and RSV, sponsored by VA Office of Research and Development.

NCT06160128 is a study of Influenza and RSV that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 400,000 participants, above the 34,240-participant average among 156 other Influenza trials with a reported enrollment target (1068% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06160128, a study of Influenza and RSV, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
400,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.

Primary Outcome

The odds of receipt of any COVID-19 pharmacotherapy, including sotrovimab, nirmatrelvir boosted with ritonavir, molnupiravir, or remdesivir were estimated using multivariable logistic regression

Study Locations (1)

Oregon

  • VA Portland Health Care System, Portland, OR - Portland

Trial Details

FieldValue
Enrollment Target 400,000 participants
Start Date 2022-09-26
Est. Completion 2027-09-30
VA Office of Research and Development

1,668 total trials

What NCT06160128 shows while recruiting

NCT06160128 is an observational study that tracks outcomes without assigning an intervention. Its 400,000 participants enrollment target places it among the larger protocols in the corpus, above the 34,240-participant average among 156 other Influenza trials with a reported enrollment target (1068% higher).

The record links to 3 conditions, with Influenza appearing as the primary indexed condition, and to 0 interventions.

NCT06160128 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT06160128 about?

NCT06160128 is a clinical study titled "Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)". The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treat...

What is the current status of trial NCT06160128?

This trial is currently recruiting. The enrollment target is 400,000 participants. The study started on 2022-09-26. Estimated completion is 2027-09-30.

What conditions does trial NCT06160128 study?

This clinical trial studies the following conditions: Influenza, RSV, COVID-19, SARS-CoV-2 Infection.

Who is sponsoring clinical trial NCT06160128?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06160128 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06160128's enrollment target sits among peer trials

400,000 3rd of 156 higher than 154 of 156 other Influenza trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06934239 · 400,000 participants · Phase 4

    A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

  • NCT06342375 · 425,000 participants · NA

    Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage

  • NCT05668637 · 318,542 participants

    Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

  • NCT05365048 · 301,201 participants · NA

    Provider Recommendation and HPV Vaccination

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06160128, the US trial registry maintained by the National Library of Medicine. NCT06160128 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.